Titre :

Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review

Auteur(s) :

Deshayes, Samuel [Auteur]
Georgin-Lavialle, Sophie [Auteur]
Hot, Arnaud [Auteur]
Durel, Cecile-Audrey [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Rouanes, Nicolas [Auteur]
Audia, Sylvain [Auteur]
Le Gallou, Thomas [Auteur]
Quartier, Pierre [Auteur]
Urbanski, Geoffrey [Auteur]
Messer, Laurent [Auteur]
Klein, Stephane [Auteur]
De Boysson, Hubert [Auteur]
Bienvenu, Boris [Auteur]
Grateau, Gilles [Auteur]
Aouba, Achille [Auteur]

Titre de la revue :

The Internet Journal of Rheumatology

Nom court de la revue :

J. Rheumatol.

Numéro :

45

Pagination :

425-429

Date de publication :

2018-03

ISSN :

0315-162X

Mot(s)-clé(s) :

INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN ANAKINRA
HEREDITARY AUTOINFLAMMATORY DISEASES
CANAKINUMAB
MEVALONATE KINASE DEFICIENCY

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objective. To report efficacy and tolerance of interleukin 1 blockade in adult patients with mevalonate kinase deficiency (MKD). Methods. We retrospectively collected data on 13 patients with MKD who had received anakinra ...
Lire la suite >Objective. To report efficacy and tolerance of interleukin 1 blockade in adult patients with mevalonate kinase deficiency (MKD). Methods. We retrospectively collected data on 13 patients with MKD who had received anakinra (n = 10) and canakinumab (n = 7). Results. Anakinra resulted in complete or partial remission in 3/10 and 5/10 patients, respectively, and no efficacy in 2/10, but a switch to canakinumab led to partial remission. Canakinumab resulted in complete or partial remission in 3/7 and 4/7 patients, respectively. Conclusion. These data support frequent partial responses, showing a better response with canakinumab. The genotype and therapeutic outcomes correlation should help in the personalization of treatment.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T14:35:12Z
2024-01-25T11:25:22Z